3 Things You Need to Know about OvaNext

Layla Shahmirzadi, MS, CGC, LGC
September 4th, 2018

Ovarian cancer can often appear quietly, with non-specific symptoms, making it difficult to detect at an early stage. Knowing if someone is at an increased risk for ovarian and other cancers can be critical for guiding early detection, prevention, or treatment. Genetic testing can help identify patients with hereditary cancer, allowing for personalized risk counseling and medical management.

OvaNext is designed to give you accurate and clinically meaningful information to help you offer personalized treatment, guide early detection and prevent cancer for patients and their families.

Here are 3 key things you need to know about OvaNext:

Which genes are included? OvaNext analyzes 25 genes associated with hereditary ovarian, uterine, and breast cancer. Testing genes beyond BRCA1 and BRCA2 can significantly increase detection of patients with hereditary gynecologic cancer.
Who should be tested? OvaNext is a great tool for patients with a personal or family history suggestive of hereditary gynecologic cancer. Some signs include:
1. Young Cancer: Breast or uterine cancer diagnosed at <50y
2. Rare Cancer: Ovarian cancer at any age
3. Multiple Cancers:
  - >2 individuals on the same side of the family with breast, ovarian, uterine, or other cancers
  - >2 primary cancers in the same person
Does this test impact medical management? The majority of genes on OvaNext have published medical management guidelines. In fact, 93% of positive results from OvaNext are clinically actionable.¹With an average turnaround time of 11 days, this test gives you results quickly allowing you to better guide treatment and management.

Learn more about OvaNext here or request additional information from your local Genetic Specialist.

Namey T et al. Multigene Panel Testing Increases the Detection of Clinically-Actionable Mutations in Ovarian Cancer Patients. Poster Presentation SGO 2018.

Find Answers & Improve Patient Care

Ambry is committed to delivering the most accurate genetic test results possible. Learn more about our products today.

Contact A Sales Rep

Love this article?

Get stories just like it, delivered right to your inbox.

Author

Layla Shahmirzadi, MS, CGC, LGC

Layla Shahmirzadi Mowlavi earned her M.S. in Human Genetics and Genetic Counseling from Stanford University in 2012. She also holds an M.S. in Biotechnology from Johns Hopkins University and a B.S. in Psychology from UC Davis. Layla has been with Ambry Genetics since 2012 and has held several roles prior to becoming a Genetic Specialist including Exome Reporting Genetic Counselor, Clinical Genomics Product Manager, and Product Development Manager. Prior to beginning her career at Ambry, Layla also served as Clinical Assistant at the UCSF Cancer Risk Program. Layla is a member of the National Society of Genetic Counselors (NSGC) and board certified by the American Board of Genetic Counseling (ABGC).

DISCLAIMER: THIS BLOG DOES NOT PROVIDE MEDICAL ADVICE

The information, including but not limited to, text, graphics, images and other material contained on this blog are for informational purposes only. The purpose of this blog is to promote broad understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this blog. Ambry Genetics Corporation does not recommend or endorse any specific tests, physicians, products, procedures, opinions or other information that may be mentioned on this blog. Reliance on any information appearing on this blog is solely at your own risk.